Oscotec FY 2025 Annual ReportBeta
Oscotec annual report for FY 2025, filed with DART (Korea Financial Supervisory Service) on March 19, 2026. This page provides AI-powered English analysis including business overview, management discussion & analysis (MD&A), risk factors, and KIFRS consolidated financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE).
Oscotec FY 2025 Annual Report Analysis
Business Overview
- • Core revenue from synthetic new drug licensing milestone KRW 89.1B (89.3% of total sales) in FY2025
- • Alzheimer’s disease antibody ADEL-Y01 licensed to global pharma Dec 2025, FDA clinical phase 1 ongoing
Management Discussion & Analysis
- • Revenue KRW 99,838M (+193.58% YoY), Operating profit KRW 52,081M, Net profit KRW 54,397M, all turned positive vs loss prior year
- • Biggest driver: Technology transfer revenue increased 222.70% to KRW 89,144M due to overseas milestone from lung cancer drug Lezatinib and contract for Adel-Y01
Risk Factors
- • Foreign exchange risk arises from recognized assets and liabilities denominated in non-functional currencies
- • Foreign exchange risk managed via currency forward contracts when hedging deemed necessary
Oscotec FY 2025 Key Financial MetricsDART
Total Assets
KRW 229.9B
▲ +34.6% YoY
Operating Cash Flow
KRW 8.3B
▲ +131.9% YoY
Source: KIFRS consolidated financial data from Oscotec annual report on DART. All figures in KRW.
Source: DART (Korea Financial Supervisory Service) · AI summaries generated from the original Korean filing (English output) · Beta: coverage is expanding